These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 9331103)

  • 1. Mutation frequency and spectrum in lymphocytes of small cell lung cancer patients receiving etoposide chemotherapy.
    Karnaoukhova L; Moffat J; Martins H; Glickman B
    Cancer Res; 1997 Oct; 57(19):4393-407. PubMed ID: 9331103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
    Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
    Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Point mutations of the topoisomerase IIalpha gene in patients with small cell lung cancer treated with etoposide.
    Kubo A; Yoshikawa A; Hirashima T; Masuda N; Takada M; Takahara J; Fukuoka M; Nakagawa K
    Cancer Res; 1996 Mar; 56(6):1232-6. PubMed ID: 8640804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
    Miller AA; Al Omari A; Murry DJ; Case D
    Lung Cancer; 2006 Dec; 54(3):379-85. PubMed ID: 17049403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular analysis of mutations at the HPRT and TK loci of human lymphoblastoid cells after combined treatments with 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosinedagger.
    Meng Q; Su T; O'Neill JP; Walker VE
    Environ Mol Mutagen; 2002; 39(4):282-95. PubMed ID: 12112380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
    Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P
    Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple biological markers in germ cell tumor patients treated with platinum-based chemotherapy.
    Perera FP; Motzer RJ; Tang D; Reed E; Parker R; Warburton D; O'Neill P; Albertini R; Bigbee WL; Jensen RH
    Cancer Res; 1992 Jul; 52(13):3558-65. PubMed ID: 1319825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacology of chronic oral etoposide in patients with small cell and non-small cell lung cancer.
    Zucchetti M; Pagani O; Torri V; Sessa C; D'Incalci M; De Fusco M; de Jong J; Gentili D; Martinelli G; Tinazzi A
    Clin Cancer Res; 1995 Dec; 1(12):1517-24. PubMed ID: 9815952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide.
    Hammond LA; Eckardt JR; Ganapathi R; Burris HA; Rodriguez GA; Eckhardt SG; Rothenberg ML; Weiss GR; Kuhn JG; Hodges S; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 1998 Jun; 4(6):1459-67. PubMed ID: 9626463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA adduct formation and T lymphocyte mutation induction in F344 rats implanted with tumorigenic doses of 1,6-dinitropyrene.
    Beland FA
    Res Rep Health Eff Inst; 1995 Oct; (72):1-27; discussion 29-39. PubMed ID: 11381742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
    Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S;
    Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy for small cell lung carcinoma: the Greenlane Hospital experience 1993-1995.
    Lee YC; McCrystal MR; Christmas TI
    N Z Med J; 1998 Nov; 111(1078):451-2, 453-4. PubMed ID: 9891564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062).
    Miller AA; Rosner GL; Ratain MJ; Hollis DR; Green MR; Schilsky RL
    Clin Cancer Res; 1997 May; 3(5):719-25. PubMed ID: 9815741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new T-lymphocyte cloning assay for detection of in vivo mutations in the human hypoxanthine-guanine phosphoribosyltransferase gene.
    Uematsu K; Yasuda J; Sekine T; Sugano K; Kudoh S; Sekiya T
    Environ Mol Mutagen; 1997; 30(1):31-9. PubMed ID: 9258327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequencing topotecan and etoposide plus cisplatin to overcome topoisomerase I and II resistance: a pharmacodynamically based Phase I trial.
    Aisner J; Musanti R; Beers S; Smith S; Locsin S; Rubin EH
    Clin Cancer Res; 2003 Jul; 9(7):2504-9. PubMed ID: 12855624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study.
    Ettinger DS; Berkey BA; Abrams RA; Fontanesi J; Machtay M; Duncan PJ; Curran WJ; Movsas B; Byhardt RW;
    J Clin Oncol; 2005 Aug; 23(22):4991-8. PubMed ID: 15939930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multimodality treatment including early high-dose chemotherapy with peripheral blood stem cell transplantation in limited-disease small cell lung cancer.
    Brugger W; Fetscher S; Hasse J; Frommhold H; Pressler K; Mertelsmann R; Engelhardt R; Kanz L
    Semin Oncol; 1998 Feb; 25(1 Suppl 2):42-8. PubMed ID: 9535211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: the Japan Clinical Oncology Lung Cancer Study Group Trial (JCOG9101).
    Tsuchiya R; Suzuki K; Ichinose Y; Watanabe Y; Yasumitsu T; Ishizuka N; Kato H
    J Thorac Cardiovasc Surg; 2005 May; 129(5):977-83. PubMed ID: 15867769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topotecan and etoposide as first-line therapy for extensive disease small cell lung cancer: a phase II trial of a platinum-free regimen.
    Reck M; Groth G; Buchholz E; Goetz E; Gatzemeier U; Manegold C
    Lung Cancer; 2005 Jun; 48(3):409-13. PubMed ID: 15893010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cisplatin/etoposide chemotherapy combined with twice daily thoracic radiotherapy for limited small-cell lung cancer: a clinical phase II trial.
    Chen GY; Jiang GL; Wang LJ; Qian H; Fu XL; Yang H; Wu KL; Zhao S
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):70-5. PubMed ID: 15629596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.